EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial ( TRANSITION ‐ T2D )

Paloma Rodriguez, Nikki Breslaw, Huijun Xiao, Jim Bena, Kimberly Jenkins, Diana Isaacs, Keren Zhou, Marcio L Griebeler, Bartolome Burguera, Kevin M Pantalone iD, TRANSITION‐T2D Investigators

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16057 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Paloma Rodriguez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Glycated Hemoglobin. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Inc, Investigator Sponsored Studies Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The study aims to examine the outcome of replacement of prandial insulin with once‐weekly subcutaneous semaglutide in people with type 2 diabetes reasonably controlled on multiple daily insulin injections (MDI). Materials and Methods This single‐centre, randomised, open‐label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day. Participants were assigned 2:1 to subcutaneous semaglutide 1.0 mg plus insulin degludec, or to continue MDI. The primary outcome was percentage of subjects maintaining HbA1c ≤7.5% (58 mmol/mol) at Week 26.

Results

At Week 26, 90% of semaglutide and 75% of MDI subjects maintained HbA 1c ≤7.5% (≤58 mmol/mol) ( p = 0.18). Mean changes (95% CI) in HbA 1c , weight and percentage body weight for semaglutide versus MDI, respectively, were −0.5% (−0.7, −0.3) versus 0.0% (−0.3, 0.3; p = 0.009); −8.9 kg (−9.9, −7.8) versus 1.5 kg (−0.1, 3.1; p < 0.001); and −8.6% (−9.6, −7.6) versus 1.4% (0.0, 2.8; p < 0.001). Insulin TDD decreased 56.0% (−62.3, −49.7) with semaglutide and increased 6.7% (−2.5, 16.0) with MDI ( p < 0.001). Among semaglutide subjects, 58% reduced insulin TDD > 50%, 97.5% stopped prandial insulin and 45% lost >10% body weight. Participant treatment satisfaction scores trended higher with semaglutide. Hypoglycaemia frequency was similar between groups.

Conclusions

In people with type 2 diabetes well controlled (HbA 1c ≤7.5% [≤58 mmol/mol]) on MDI ≤120 units/day, replacing multiple daily injections of prandial insulin with once‐weekly subcutaneous semaglutide can maintain and even improve HbA 1c , lower body weight and lessen the burden of management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsGlycated HemoglobinInsulin, Long-ActingHumansMaleFemaleMiddle AgedInjections, SubcutaneousAgedDrug Administration ScheduleBlood GlucoseDrug Therapy, CombinationTreatment OutcomeGlycemic ControlInsulinAdultHypoglycemiaSemaglutide

Stichwörter der Autor:innen

GLP‐1 agonistbasal bolusbody weightglycaemic controltype 2 diabetesweight change

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlycated HemoglobinInsulin, Long-ActingBlood GlucoseInsulinSemaglutidehemoglobin A1c protein, humaninsulin degludec

Autor:innen und Institutionen

  • Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Lerner Research Institute, Clinical Research Unit, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Kevin M Pantalone

Förderung

  • Novo Nordisk Inc
  • Investigator Sponsored Studies Program

Zitieren

APA

Rodriguez, P., Breslaw, N., Xiao, H., Bena, J., Jenkins, K., Isaacs, D., Zhou, K., Griebeler, M. L., Burguera, B., Pantalone, K. M., & TRANSITION‐T2D Investigators (2025). De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial ( TRANSITION ‐ T2D ). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16057

Vancouver

Rodriguez P, Breslaw N, Xiao H, Bena J, Jenkins K, Isaacs D, et al. De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial ( TRANSITION ‐ T2D ). Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16057

BibTeX
@article{Rodriguez2025,
  author = {Rodriguez, Paloma and Breslaw, Nikki and Xiao, Huijun and Bena, Jim and Jenkins, Kimberly and Isaacs, Diana and Zhou, Keren and Griebeler, Marcio L and Burguera, Bartolome and Pantalone, Kevin M and TRANSITION‐T2D Investigators, TRANSITION‐T2D Investigators},
  title = {De‐intensification of basal‐bolus therapy by replacing prandial insulin with once‐weekly subcutaneous semaglutide in individuals with well‐controlled type 2 diabetes: A single‐centre, open‐label randomised trial ( TRANSITION ‐ T2D )},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16057}
}
Kostenlos starten →